Drugs / Ganovo
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04291729 | Feb → Mar 2020 | COVID-19 | The Ninth Hospital of Nanchang | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-12-03 | Ascletis Pharmaceuticals Co., Ltd. | Ascletis Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-oral Direct Anti-HCV Therapy ascletis.com ↗ |
| 2018-10-15 | Ascletis Pharmaceuticals Co., Ltd. | Ascletis' Ganovo is Eligible for Shaoxing Government Funding Subsidy Program to Treat HCV Patients ascletis.com ↗ |
| 2018-09-26 | Ascletis Pharmaceuticals Co., Ltd. | Ganovo® Enrolled in the Basic Medical Insurance of Tianjin--Capped Reimbursement-Per-Patient Pilot Program ascletis.com ↗ |
| 2018-07-30 | Ascletis Pharmaceuticals Co., Ltd. | Ganovo® Phase III Clinical Study Won the Top Award at the Infectious Disease National Congress of Chinese Medical Association ascletis.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ganovo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04291729 ↗ |
| Known as | Danoprevir | “Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection” NCT04291729 ↗ |
| Action | Inhibit | “Ganovo, an oral Hepatitis C virus protease inhibitor” NCT04291729 ↗ |
| Route | Oral | “Ganovo, an oral Hepatitis C virus protease inhibitor” NCT04291729 ↗ |